Given the extensive use of sulfonylureas and preferential place of SGLT-2 inhibitors for the treatment of type 2 diabetes, the risk associated with the combination therapy would result in a substantial number of cases of induced hypoglycemia. The gene discussed is SLC5A2; the disease is Hypoglycemia.